Calais J, Morris M, Kendi A, Kalebasty A, Tutrone R, Anderson M
J Nucl Med. 2024; 65(11):1666-1671.
PMID: 39362764
PMC: 11533911.
DOI: 10.2967/jnumed.124.268363.
Grus T, Lahnif H, Bausbacher N, Miederer M, Rosch F
Front Nucl Med. 2024; 2:892147.
PMID: 39354968
PMC: 11440839.
DOI: 10.3389/fnume.2022.892147.
Jiang Z, Guo J, Hu L, Yang S, Meng B, Tang Q
Oncol Lett. 2024; 27(4):188.
PMID: 38486944
PMC: 10938285.
DOI: 10.3892/ol.2024.14321.
Pang W, Cheng S, Du Z, Du S
Front Oncol. 2023; 13:1145759.
PMID: 36959787
PMC: 10030046.
DOI: 10.3389/fonc.2023.1145759.
Wilson Z, Xu G, Tewari S, Lu Y
Am J Nucl Med Mol Imaging. 2023; 13(1):1-10.
PMID: 36923600
PMC: 10009469.
Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer.
Zhou H, Gao Y, Liu Y, Wu Y, Fang Y, Wang B
Amino Acids. 2021; 54(1):147-155.
PMID: 34800176
PMC: 8810462.
DOI: 10.1007/s00726-021-03102-8.
Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.
Sun J, Lin Y, Wei X, Ouyang J, Huang Y, Ling Z
Front Oncol. 2021; 11:649171.
PMID: 33981607
PMC: 8107478.
DOI: 10.3389/fonc.2021.649171.
Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis.
Pan K, Wang J, Wang C, Nikzad A, Kong F, Jian L
Front Oncol. 2021; 10:597422.
PMID: 33680924
PMC: 7925846.
DOI: 10.3389/fonc.2020.597422.
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Miyahira A, Pienta K, Babich J, Bander N, Calais J, Choyke P
Prostate. 2020; 80(15):1273-1296.
PMID: 32865839
PMC: 8442561.
DOI: 10.1002/pros.24056.
Recent updates and developments in PET imaging of prostate cancer.
Rowe S, Johnson G, Pomper M, Gorin M, Behr S
Abdom Radiol (NY). 2020; 45(12):4063-4072.
PMID: 32417934
DOI: 10.1007/s00261-020-02570-y.
Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern.
Yin Y, Paller C, Pomper M, Pienta K, Gorin M, Rowe S
World J Nucl Med. 2020; 18(4):424-427.
PMID: 31933562
PMC: 6945367.
DOI: 10.4103/wjnm.WJNM_50_18.
F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.
Werner R, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel F
Theranostics. 2020; 10(1):1-16.
PMID: 31903102
PMC: 6929634.
DOI: 10.7150/thno.37894.
Prospective Comparison of PET Imaging with PSMA-Targeted F-DCFPyL Versus NaF for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe S, Li X, Trock B, Werner R, Frey S, Digianvittorio M
J Nucl Med. 2019; 61(2):183-188.
PMID: 31451492
PMC: 8801956.
DOI: 10.2967/jnumed.119.227793.
A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?.
Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R
World J Urol. 2019; 37(11):2343-2353.
PMID: 30706122
DOI: 10.1007/s00345-019-02652-7.
A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion.
Harmon S, Mena E, Shih J, Adler S, McKinney Y, Bergvall E
Oncotarget. 2019; 9(102):37676-37688.
PMID: 30701023
PMC: 6340866.
DOI: 10.18632/oncotarget.26481.
Discovery of F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions.
Zlatopolskiy B, Endepols H, Krapf P, Guliyev M, Urusova E, Richarz R
J Nucl Med. 2018; 60(6):817-823.
PMID: 30389823
PMC: 6581226.
DOI: 10.2967/jnumed.118.218495.
Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y, Werner R, Higuchi T, Lapa C, Pienta K, Pomper M
J Nucl Med. 2018; 60(4):511-516.
PMID: 30190303
PMC: 6448464.
DOI: 10.2967/jnumed.118.217653.
F-NaF/RaCl theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.
Jadvar H, Colletti P
Br J Radiol. 2018; 91(1091):20170948.
PMID: 29630398
PMC: 6475949.
DOI: 10.1259/bjr.20170948.
A Prospective Comparison of F-Sodium Fluoride PET/CT and PSMA-Targeted F-DCFBC PET/CT in Metastatic Prostate Cancer.
Harmon S, Bergvall E, Mena E, Shih J, Adler S, McKinney Y
J Nucl Med. 2018; 59(11):1665-1671.
PMID: 29602821
PMC: 6225539.
DOI: 10.2967/jnumed.117.207373.
Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT.
Phillips R, Gorin M, Rowe S, Pomper M, Pienta K, Ross A
Urol Case Rep. 2017; 16:86-88.
PMID: 29226093
PMC: 5705796.
DOI: 10.1016/j.eucr.2017.11.021.
